drugset
drugset / Trial / NCT01501383

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

NCT01501383 ↗

Phase 2 Terminated 55 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of VX-765 in subjects with treatment-resistant partial epilepsy.

Timeline

Start
2011-12
Primary completion
2013-08
Completion
—

Outcome

Outcome not reported

Stopped: “Terminated by Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Belnacasan Small molecule — —

Indications

epilepsy